{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:15:55Z","timestamp":1790511355308,"version":"4.1.0"},"reference-count":83,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["BIOT"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The world continues to be in the midst of a distressing pandemic of coronavirus disease 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel virus with multiple antigenic systems. The virus enters via nasopharynx, oral and infects cells by the expression of the spike protein, and enters the lungs using the angiotensin-converting enzyme-2 receptor. The spectrum of specific immune responses to SARS-CoV-2 virus infection is increasingly challenging as frequent mutations have been reported and their antigen specificity varies accordingly. The development of monoclonal antibodies (mAbs) will have a more significant advantage in suppressing SARS-CoV-2 virus infectivity. Recently, mAbs have been developed to target specific neutralizing antibodies against SARS-CoV-2 infection. The use of the therapeutic index of mAbs that can elicit neutralization by binding to the viral spike protein and suppress the cytokine network is a classic therapeutic approach for a potential cure. The development of mAbs against B-cell function as well as inhibition of the cytokine network has also been a focus in recent research. Recent studies have demonstrated the efficacy of mAbs as antibody cocktail preparations against SARS-CoV-2 infection. Target specific therapeutic accomplishment with mAbs, a milestone in the modern therapeutic age, can be used to achieve a specific therapeutic strategy to suppress SARS-CoV-2 virus infection. This review focuses on the molecular aspects of the cytokine network and antibody formation to better understand the development of mAbs against SARS-CoV-2 infection.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1872208316666220106110014","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T11:54:26Z","timestamp":1641556466000},"page":"64-78","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Monoclonal Antibodies and their Target Specificity Against\nSARS-CoV-2 Infections: Perspectives and Challenges"],"prefix":"10.2174","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2391-4679","authenticated-orcid":true,"given":"Mohammed A.","family":"Bakkari","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Kingdom of Saudi\nArabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4860-0166","authenticated-orcid":true,"given":"Sivakumar Sivagurunathan","family":"Moni","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Kingdom of Saudi\nArabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1389-1899","authenticated-orcid":true,"given":"Muhammad Hadi","family":"Sultan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Kingdom of Saudi\nArabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-8408","authenticated-orcid":true,"given":"Osama A.","family":"Madkhali","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Kingdom of Saudi\nArabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"100124","DOI":"10.1016\/j.onehlt.2020.100124","volume":"9","author":"El Zowalaty M.E.","year":"2020","unstructured":"El Zowalaty M.E.; J&#xE4;rhult J.D.; From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans - Call for a One Health approach. One Health 2020,9(9),100124","journal-title":"One Health"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1473-3099(20)30195-X","volume":"20","author":"Baud D.","year":"2020","unstructured":"Baud D.; Qi X.; Nielsen-Saines K.; Musso D.; Pomar L.; Favre G.; Real estimates of mortality following COVID-19 infection. Lancet Infect Dis 2020,20(7),773","journal-title":"Lancet Infect Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"Zhou P.","year":"2020","unstructured":"Zhou P.; Yang X.L.; Wang X.G.; Hu B.; Zhang L.; Zhang W.; Si H.R.; Zhu Y.; Li B.; Huang C.L.; Chen H.D.; Chen J.; Luo Y.; Guo H.; Jiang R.D.; Liu M.Q.; Chen Y.; Shen X.R.; Wang X.; Zheng X.S.; Zhao K.; Chen Q.J.; Deng F.; Liu L.L.; Yan B.; Zhan F.X.; Wang Y.Y.; Xiao G.F.; Shi Z.L.; A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020,579(7798),270-273","journal-title":"Nature"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/jmv.25798","volume":"92","author":"Khalili J.S.","year":"2020","unstructured":"Khalili J.S.; Zhu H.; Mak N.S.A.; Yan Y.; Zhu Y.; Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol 2020,92(7),740-746","journal-title":"J Med Virol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1097\/MJT.0000000000001402","volume":"28","author":"Bryant A.","year":"2021","unstructured":"Bryant A.; Lawrie T.A.; Dowswell T.; Fordham E.J.; Mitchell S.; Hill S.R.; Tham T.C.; Ivermectin for prevention and treatment of COVID-19 infection: A systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther 2021,28(4),e434-e460","journal-title":"Am J Ther"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"Wang M.","year":"2020","unstructured":"Wang M.; Cao R.; Zhang L.; Yang X.; Liu J.; Xu M.; Shi Z.; Hu Z.; Zhong W.; Xiao G.; Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020,30(3),269-271","journal-title":"Cell Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"106519","DOI":"10.1016\/j.intimp.2020.106519","volume":"84","author":"di Mauro G.","year":"2020","unstructured":"di Mauro G.; Scavone C.; Rafaniello C.; Rossi F.; Capuano A.; SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment. Int Immunopharmacol 2020,84,106519","journal-title":"Int Immunopharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/all.14364","volume":"75","author":"Azkur A.K.","year":"2020","unstructured":"Azkur A.K.; Akdis M.; Azkur D.; Sokolowska M.; van de Veen W.; Br&#xFC;ggen M.C.; O\u2019Mahony L.; Gao Y.; Nadeau K.; Akdis C.A.; Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020,75(7),1564-1581","journal-title":"Allergy"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/d41586-020-02324-2","volume":"584","author":"Ledford H.","year":"2020","unstructured":"Ledford H.; Evidence lags behind excitement over blood plasma as a coronavirus treatment. Nature 2020,584(7822),505","journal-title":"Nature"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/iub.1556","volume":"68","author":"Dai L.","year":"2016","unstructured":"Dai L.; Wang Q.; Qi J.; Shi Y.; Yan J.; Gao G.F.; Molecular basis of antibody-mediated neutralization and protection against flavivirus. IUBMB Life 2016,68(10),783-791","journal-title":"IUBMB Life"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1128\/CMR.00046-08","volume":"22","author":"Mogensen T.H.","year":"2009","unstructured":"Mogensen T.H.; Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009,22(2),240-273","journal-title":"Clin Microbiol Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3389\/fimmu.2018.00427","volume":"9","author":"Malkiel S.","year":"2018","unstructured":"Malkiel S.; Barlev A.N.; Atisha-Fregoso Y.; Suurmond J.; Diamond B.; Plasma cell differentiation pathways in systemic lupus erythematosus. Front Immunol 2018,9,427","journal-title":"Front Immunol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","volume":"17","author":"Zheng M.","year":"2020","unstructured":"Zheng M.; Gao Y.; Wang G.; Song G.; Liu S.; Sun D.; Xu Y.; Tian Z.; Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020,17(5),533-535","journal-title":"Cell Mol Immunol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/s41467-019-09212-y","volume":"10","author":"Zhang C.","year":"2019","unstructured":"Zhang C.; Wang X.M.; Li S.R.; Twelkmeyer T.; Wang W.H.; Zhang S.Y.; Wang S.F.; Chen J.Z.; Jin X.; Wu Y.Z.; Chen X.W.; Wang S.D.; Niu J.Q.; Chen H.R.; Tang H.; NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun 2019,10(1),1507","journal-title":"Nat Commun"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.jbior.2020.100737","volume":"77","author":"Masselli E.","year":"2020","unstructured":"Masselli E.; Vaccarezza M.; Carubbi C.; Pozzi G.; Presta V.; Mirandola P.; Vitale M.; NK cells: A double edge sword against SARS-CoV-2. Adv Biol Regul 2020,77,100737","journal-title":"Adv Biol Regul"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"580237","DOI":"10.3389\/fimmu.2020.580237","volume":"11","author":"Li M.","year":"2020","unstructured":"Li M.; Guo W.; Dong Y.; Wang X.; Dai D.; Liu X.; Wu Y.; Li M.; Zhang W.; Zhou H.; Zhang Z.; Lin L.; Kang Z.; Yu T.; Tian C.; Qin R.; Gui Y.; Jiang F.; Fan H.; Heissmeyer V.; Sarapultsev A.; Wang L.; Luo S.; Hu D.; Elevated exhaustion levels of NK and CD8+ T cells as indicators for progression and prognosis of COVID-19 disease. Front Immunol 2020,11,580237","journal-title":"Front Immunol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"Andr&#xE9; P.","year":"2018","unstructured":"Andr&#xE9; P.; Denis C.; Soulas C.; Bourbon-Caillet C.; Lopez J.; Arnoux T.; Bl&#xE9;ry M.; Bonnafous C.; Gauthier L.; Morel A.; Rossi B.; Remark R.; Breso V.; Bonnet E.; Habif G.; Guia S.; Lalanne A.I.; Hoffmann C.; Lantz O.; Fayette J.; Boyer-Chammard A.; Zerbib R.; Dodion P.; Ghadially H.; Jure-Kunkel M.; Morel Y.; Herbst R.; Narni-Mancinelli E.; Cohen R.B.; Vivier E.; Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK Cells. Cell 2018,175(7),1731-1743.e13","journal-title":"Cell"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fimmu.2017.00254","volume":"8","author":"Bhaumik S.","year":"2017","unstructured":"Bhaumik S.; Basu R.; Cellular and molecular dynamics of Th17 differentiation and its developmental plasticity in the intestinal immune response. Front Immunol 2017,8,254","journal-title":"Front Immunol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/j.jinf.2020.05.072","volume":"81","author":"Mendoza V.M.M.","year":"2020","unstructured":"Mendoza V.M.M.; Interleukin-17: A potential therapeutic target in COVID-19. J Infect 2020,81(2),e136-e138","journal-title":"J Infect"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.22377\/ajp.v14i03.3680","volume":"14","author":"Sivakumar S.M.","year":"2020","unstructured":"Sivakumar S.M.; Bremnavas I.M.; Insights on the application of MATLAB and chaotic principles to determine the targeted delivery of a smart drug delivery system against cancer in the experimental phase: A prospective approach. Asian J Pharm 2020,14(3),319-329","journal-title":"Asian J Pharm"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.26355\/eurrev_202002_20378","volume":"24","author":"Kannan S.","year":"2020","unstructured":"Kannan S.; Shaik Syed Ali P.; Sheeza A.; Hemalatha K.; COVID-19 (Novel Coronavirus 2019) - recent trends. Eur Rev Med Pharmacol Sci 2020,24(4),2006-2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","volume":"27","author":"Wu A.","year":"2020","unstructured":"Wu A.; Peng Y.; Huang B.; Ding X.; Wang X.; Niu P.; Meng J.; Zhu Z.; Zhang Z.; Wang J.; Sheng J.; Quan L.; Xia Z.; Tan W.; Cheng G.; Jiang T.; Genome composition and divergence of the novel coronavirus (2019-ncov) originating in China. Cell Host Microbe 2020,27(3),325-328","journal-title":"Cell Host Microbe"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.26508\/lsa.202000786","volume":"3","author":"Bestle D.","year":"2020","unstructured":"Bestle D.; Heindl M.R.; Limburg H.; Van Lam van T.; Pilgram O.; Moulton H.; Stein D.A.; Hardes K.; Eickmann M.; Dolnik O.; Rohde C.; Klenk H.D.; Garten W.; Steinmetzer T.; B&#xF6;ttcher-Friebertsh&#xE4;user E.; TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance 2020,3(9),2575-1077","journal-title":"Life Sci Alliance"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"Grifoni A.","year":"2020","unstructured":"Grifoni A.; Weiskopf D.; Ramirez S.I.; Mateus J.; Dan J.M.; Moderbacher C.R.; Rawlings S.A.; Sutherland A.; Premkumar L.; Jadi R.S.; Marrama D.; de Silva A.M.; Frazier A.; Carlin A.F.; Greenbaum J.A.; Peters B.; Krammer F.; Smith D.M.; Crotty S.; Sette A.; Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020,181(7),1489-1501.e15","journal-title":"Cell"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e1339","DOI":"10.1002\/cti2.1339","volume":"10","author":"Leire de C.M.","year":"2021","unstructured":"Leire de C.M.; Sonia T.V.; Roser T.P.; SARS-CoV-2 sculpts the immune system to induce sustained virus-specific na&#xEF;ve-like and memory B-cell responses. Clin Transl Immunol 2021,10(9),e1339","journal-title":"Clin Transl Immunol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","volume":"587","author":"Braun J.","year":"2020","unstructured":"Braun J.; Loyal L.; Frentsch M.; Wendisch D.; Georg P.; Kurth F.; Hippenstiel S.; Dingeldey M.; Kruse B.; Fauchere F.; Baysal E.; Mangold M.; Henze L.; Lauster R.; Mall M.A.; Beyer K.; R&#xF6;hmel J.; Voigt S.; Schmitz J.; Miltenyi S.; Demuth I.; M&#xFC;ller M.A.; Hocke A.; Witzenrath M.; Suttorp N.; Kern F.; Reimer U.; Wenschuh H.; Drosten C.; Corman V.M.; Giesecke-Thiel C.; Sander L.E.; Thiel A.; SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 2020,587(7833),270-274","journal-title":"Nature"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2174\/1871530320666200427112902","volume":"20","author":"Magrone T.","year":"2020","unstructured":"Magrone T.; Magrone M.; Jirillo E.; Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target - A perspective. Endocr Metab Immune Disord Drug Targets 2020,20(6),807-811","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41584-020-0448-7","volume":"16","author":"Galeotti C.","year":"2020","unstructured":"Galeotti C.; Bayry J.; Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol 2020,16(8),413-414","journal-title":"Nat Rev Rheumatol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/biom11071048","volume":"11","author":"Perrella F.","year":"2021","unstructured":"Perrella F.; Coppola F.; Petrone A.; Platella C.; Montesarchio D.; Stringaro A.; Ravagnan G.; Fuggetta M.P.; Rega N.; Musumeci D.; Interference of polydatin\/resveratrol in the ACE2: Spike recognition during covid-19 infection. a focus on their potential mechanism of action through computational and biochemical assays. Biomolecules 2021,11(7),1048","journal-title":"Biomolecules"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.05.20030502","author":"Woelfel R.","year":"2020","unstructured":"Woelfel R.; Victor M.C.; Wolfgang G.; Michael S.; Sabine Z.; Marcel A.M.; Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel associated transmission cluster. MedRxiv 2020","journal-title":"MedRxiv"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"Brouwer P.J.M.","year":"2020","unstructured":"Brouwer P.J.M.; Caniels T.G.; van der Straten K.; Snitselaar J.L.; Aldon Y.; Bangaru S.; Torres J.L.; Okba N.M.A.; Claireaux M.; Kerster G.; Bentlage A.E.H.; van Haaren M.M.; Guerra D.; Burger J.A.; Schermer E.E.; Verheul K.D.; van der Velde N.; van der Kooi A.; van Schooten J.; van Breemen M.J.; Bijl T.P.L.; Sliepen K.; Aartse A.; Derking R.; Bontjer I.; Kootstra N.A.; Wiersinga W.J.; Vidarsson G.; Haagmans B.L.; Ward A.B.; de Bree G.J.; Sanders R.W.; van Gils M.J.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 2020,369(6504),643-650","journal-title":"Science"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","volume":"368","author":"Wu Y.","year":"2020","unstructured":"Wu Y.; Wang F.; Shen C.; Peng W.; Li D.; Zhao C.; Li Z.; Li S.; Bi Y.; Yang Y.; Gong Y.; Xiao H.; Fan Z.; Tan S.; Wu G.; Tan W.; Lu X.; Fan C.; Wang Q.; Liu Y.; Zhang C.; Qi J.; Gao G.F.; Gao F.; Liu L.; A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 2020,368(6496),1274-1278","journal-title":"Science"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.xphs.2019.08.009","volume":"109","author":"Le Basle Y.","year":"2020","unstructured":"Le Basle Y.; Chennell P.; Tokhadze N.; Astier A.; Sautou V.; Physicochemical stability of monoclonal antibodies: A Review. J Pharm Sci 2020,109(1),169-190","journal-title":"J Pharm Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"110337","DOI":"10.1016\/j.biopha.2020.110337","volume":"129","author":"Jahanshahlu L.","year":"2020","unstructured":"Jahanshahlu L.; Rezaei N.; Monoclonal antibody as a potential anti-COVID-19. Biomed Pharmacother 2020,129,110337","journal-title":"Biomed Pharmacother"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","volume":"11","author":"Wang C.","year":"2020","unstructured":"Wang C.; Li W.; Drabek D.; Okba N.M.A.; van Haperen R.; Osterhaus A.D.M.E.; van Kuppeveld F.J.M.; Haagmans B.L.; Grosveld F.; Bosch B.J.; A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 2020,11(1),2251","journal-title":"Nat Commun"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","volume":"2","author":"Guaraldi G.","year":"2020","unstructured":"Guaraldi G.; Meschiari M.; Cozzi-Lepri A.; Milic J.; Tonelli R.; Menozzi M.; Franceschini E.; Cuomo G.; Orlando G.; Borghi V.; Santoro A.; Di Gaetano M.; Puzzolante C.; Carli F.; Bedini A.; Corradi L.; Fantini R.; Castaniere I.; Tabb&#xEC; L.; Girardis M.; Tedeschi S.; Giannella M.; Bartoletti M.; Pascale R.; Dolci G.; Brugioni L.; Pietrangelo A.; Cossarizza A.; Pea F.; Clini E.; Salvarani C.; Massari M.; Viale P.L.; Mussini C.; Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020,2(8),e474-e484","journal-title":"Lancet Rheumatol"},{"key":"ref=37","author":"Igawa T.","year":"2012","unstructured":"Igawa T.; Antibody molecules that bind to IL-6 receptor. Available from:\n2012"},{"key":"ref=38","author":"Christensen J.","unstructured":"Christensen J.;  CNN health, 2020.Available from:"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41577-020-00431-9","volume":"20","author":"Matthews D.B.","year":"2020","unstructured":"Matthews D.B.; A cocktail of antibodies for COVID-19 therapy. Nat Rev Immunol 2020,20(10),591","journal-title":"Nat Rev Immunol"},{"key":"ref=40","year":"2020","unstructured":"US FDA news release, coronavirus (covid-19) update: FDA authorizes monoclonal antibody for treatment of covid-19. Available from:\n2020"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","volume":"9","author":"Lescure F.X.","year":"2021","unstructured":"Lescure F.X.; Honda H.; Fowler R.A.; Lazar J.S.; Shi G.; Wung P.; Patel N.; Hagino O.; Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo- controlled, phase 3 trial. Lancet Respir Med 2021,9(5),522-532","journal-title":"Lancet Respir Med"},{"key":"ref=42","author":"Stevens S.","year":"2009","unstructured":"Stevens S.; Huang T.T.; Martin J.H.; High affinity antibodies to human IL-6 receptor.  Available from: \n2009"},{"key":"ref=43","author":"Gritti G.","year":"2020","unstructured":"Gritti G.; Raimondi F.; Ripamonti D.; Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. medRxiv Available from:\n2020","journal-title":"medRxiv"},{"key":"ref=44","author":"Giles-Komar J","year":"2009","unstructured":"Giles-Komar J; Knight D; Peritt D; Trikha M; Anti-IL-6 antibodies, compositions, methods and uses. Available from:\n2009"},{"key":"ref=45","year":"2020","unstructured":"US FDA news release, coronavirus (covid-19) update: FDA authorizes monoclonal antibody for treatment of covid-19, November 9th, 2020. Available from:\n2020"},{"key":"ref=46","author":"Riley G.U.S.","year":"2020","unstructured":"Riley G.U.S.; Trial of Lilly antibody therapy to end; no safety issue.  Available from: \n2020"},{"key":"ref=47","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe8263","author":"Meredith W.","year":"2020","unstructured":"Meredith W.; Eli Lilly reports promising first results for an antibody against COVID-19. Science Magazine 2020","journal-title":"Science Magazine"},{"key":"ref=48","author":"Robert C.","year":"2020","unstructured":"Robert C.; VIR-7831 GSK4182136 is a fully human anti-SARS-CoV-2 monoclonal antibody.  Available from: \n2020"},{"key":"ref=49","author":"Kempeni","year":"2017","unstructured":"Kempeni ; European patent application. Available from:\n2017"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"S1053-0770(20)31370-7","DOI":"10.1053\/j.jvca.2020.12.023","author":"Fakharian A.","year":"2021","unstructured":"Fakharian A.; Barati S.; Mohamadi M.; Dastan F.; Successful management of covid-19 with adalimumab in a post-coronary artery bypass graft surgery patient. J Cardiothorac Vasc Anesth 2021,S1053-0770(20)31370-7","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"109884","DOI":"10.1016\/j.mehy.2020.109884","volume":"143","author":"Jacobs J.J.L.","year":"2020","unstructured":"Jacobs J.J.L.; Neutralizing antibodies mediate virus-immune pathology of COVID-19. Med Hypotheses 2020,143,109884","journal-title":"Med Hypotheses"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","volume":"182","author":"Li Q.","year":"2020","unstructured":"Li Q.; Wu J.; Nie J.; Zhang L.; Hao H.; Liu S.; Zhao C.; Zhang Q.; Liu H.; Nie L.; Qin H.; Wang M.; Lu Q.; Li X.; Sun Q.; Liu J.; Zhang L.; Li X.; Huang W.; Wang Y.; The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 2020,182(5),1284-1294.e9","journal-title":"Cell"},{"key":"ref=53","author":"Robblee J.","year":"2015","unstructured":"Robblee J.; Collins B.E.; Kaundinya G.; Bosques C.J.; Methods related to bevacizumab.  Available from: \n2015"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.26.20159756","author":"Pang J.","year":"2020","unstructured":"Pang J.; Xu F.; Aondio G.; efficacy and tolerability of bevacizumab in patients with severe Covid -19. medRxiv 2020","journal-title":"medRxiv"},{"key":"ref=55","author":"Robblee J.","year":"2015","unstructured":"Robblee J.; Collins BD.; Kaundinya G.; Bosques C.J.;  Methods related to rituximab.Available from:\n2015"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1710-1492-9-39","volume":"9","author":"Dasgupta A.","year":"2013","unstructured":"Dasgupta A.; Radford K.; Arnold D.M.; Thabane L.; Nair P.; The effects of rituximab on serum IgE and BAFF. Allergy Asthma Clin Immunol 2013,9(1),39","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"L687","DOI":"10.1152\/ajplung.00304.2016","volume":"311","author":"Polverino F.","year":"2016","unstructured":"Polverino F.; Seys L.J.; Bracke K.R.; Owen C.A.; B cells in chronic obstructive pulmonary disease: Moving to center stage. Am J Physiol Lung Cell Mol Physiol 2016,311(4),L687-L695","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1016\/S2665-9913(20)30270-8","volume":"2","author":"Mehta P.","year":"2020","unstructured":"Mehta P.; Porter J.C.; Chambers R.C.; Isenberg D.A.; Reddy V.; B-cell depletion with rituximab in the COVID-19 pandemic: Where do we stand? Lancet Rheumatol 2020,2(10),e589-e590","journal-title":"Lancet Rheumatol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/d41586-020-02965-3","volume":"587","author":"Ledford H.","year":"2020","unstructured":"Ledford H.; The race to make COVID antibody therapies cheaper and more potent. Nature 2020,587(7832),18","journal-title":"Nature"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"22370","DOI":"10.1038\/s41598-020-79036-0","volume":"10","author":"Esparza T.J.","year":"2020","unstructured":"Esparza T.J.; Martin N.P.; Anderson G.P.; Goldman E.R.; Brody D.L.; High affinity nanobodies block SARS- CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. Sci Rep 2020,10(1),22370","journal-title":"Sci Rep"},{"key":"ref=61","year":"2010","unstructured":"Karen Silence, 2010. Nanobodies for the treatment of aggregation-mediated disorders.  Available from: \n2010"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.14.339150","author":"Piepenbrink M.S.","year":"2020","unstructured":"Piepenbrink M.S.; Park J.G.; Oladunni F.S.; Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. BioRxiv 2020","journal-title":"BioRxiv"},{"key":"ref=63","year":"2020","unstructured":"Clinical trials, 2020. A phase 2 study of human monoclonal antibodies, BRII-196 and BRII-198 Available from: \n2020"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bj.2020.11.011","volume":"44","author":"Jaworski J.P.","year":"2021","unstructured":"Jaworski J.P.; Neutralizing monoclonal antibodies for COVID-19 treatment and prevention. Biomed J 2021,44(1),7-17","journal-title":"Biomed J"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1161\/ATVBAHA.118.312314","volume":"39","author":"Voors-Pette C.","year":"2019","unstructured":"Voors-Pette C.; Lebozec K.; Dogterom P.; Jullien L.; Billiald P.; Ferlan P.; Renaud L.; Favre-Bulle O.; Avenard G.; Machacek M.; Pl&#xE9;tan Y.; Jandrot-Perrus M.; Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol 2019,39(5),956-964","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/jcph.1616","volume":"60","author":"Renaud L.","year":"2020","unstructured":"Renaud L.; Lebozec K.; Voors-Pette C.; Dogterom P.; Billiald P.; Jandrot Perrus M.; Pletan Y.; Machacek M.; Population pharmacokinetic\/pharmacodynamic modeling of glenzocimab (ACT017) a Glycoprotein VI inhibitor of collagen-induced platelet aggregation. J Clin Pharmacol 2020,60(9),1198-1208","journal-title":"J Clin Pharmacol"},{"key":"ref=67","year":"2020","unstructured":"ClinicalTrials. Glenzocimab in SARS-Cov-2 Acute Respiratory Distress syndrome Related to COVID-19 (GARDEN) Available from: \n2020"},{"key":"ref=68","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.08.20209411","author":"Thwaites R.S.","year":"2020","unstructured":"Thwaites R.S.; Sevilla Uruchurtu A.S.; Siggins M.; Elevated antiviral, myeloid and endothelial inflammatory markers in severe COVID-19. medRxiv 2020","journal-title":"medRxiv"},{"key":"ref=69","year":"2021","unstructured":"Investigating otilimab in patients with severe pulmonary covid-19 related disease (OSCAR). ClinicalTrials Available from: \n2021"},{"key":"ref=70","year":"2021","unstructured":"Dios CURE to develop highly specific single-chain antibodies against SARS- CoV-2. Dios Cure Therapeutics Available from: \n2021"},{"key":"ref=71","year":"2021","unstructured":"GSK Available from: \n2021"},{"key":"ref=72","year":"2021","unstructured":"GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives emergency use authorization from the us FDA for treatment of mild-to-moderate covid-19 in high-risk adults and pediatric patients. Intrado Global Newswire Available from: \n2021"},{"key":"ref=73","unstructured":"NEWS release FDA authorizes monoclonal antibodies for treatment of COVID-19. US FDAAvailable from:"},{"key":"ref=74","year":"2020","unstructured":"AZD7442Available from:\n2020"},{"key":"ref=75","unstructured":"Lenzilumab significantly improves survival in hospitalised COVID-19 patients. Humanigen Inc, 2021 Available from:"},{"key":"ref=76","unstructured":"Burlingame, 2020. Humanigen receives US patent for lenzilumab to treat cytokine storm and neurotoxicity related to CAR-T cell therapy.  Available from:"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"392407","DOI":"10.1101\/2020.11.21.392407","author":"Wenyang Z.","year":"2020","unstructured":"Wenyang Z.; Chang Xu.; Pingping W.; Meng L.; Zhaochun X.; Rui C.; Xiyun J.; Yu G.; Guangfu X.; Liran Huan N.; Qinghua J.; N439K variant in spike protein may alter the infection efficiency and antigenicity of SARS-CoV-2 based on molecular dynamics simulation. bioRxiv 2020,392407","journal-title":"bioRxiv"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1038\/s41467-020-19808-4","volume":"11","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Jackson C.B.; Mou H.; Ojha A.; Peng H.; Quinlan B.D.; Rangarajan E.S.; Pan A.; Vanderheiden A.; Suthar M.S.; Li W.; Izard T.; Rader C.; Farzan M.; Choe H.; SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun 2020,11(1),6013","journal-title":"Nat Commun"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"e123158","DOI":"10.1172\/jci.insight.123158","volume":"4","author":"Liu L.","year":"2019","unstructured":"Liu L.; Wei Q.; Lin Q.; Fang J.; Wang H.; Kwok H.; Tang H.; Nishiura K.; Peng J.; Tan Z.; Wu T.; Cheung K.W.; Chan K.H.; Alvarez X.; Qin C.; Lackner A.; Perlman S.; Yuen K.Y.; Chen Z.; Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 2019,4(4),e123158","journal-title":"JCI Insight"},{"key":"ref=80","unstructured":"New COVID-19 Variants. CDC: Centres for disease control and prevention, 2021.  Available from:"},{"key":"ref=81","author":"Sara R.","unstructured":"Sara R.; The U.K. coronavirus mutation is worrying but not terrifying. Sci Am Available from:","journal-title":"Sci Am"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.tips.2020.07.004","volume":"41","author":"Renn A.","year":"2020","unstructured":"Renn A.; Fu Y.; Hu X.; Hall M.D.; Simeonov A.; Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2. Trends Pharmacol Sci 2020,41(11),815-829","journal-title":"Trends Pharmacol Sci"},{"key":"ref=83","year":"2021","unstructured":"Globe Newswire Available from: \n2021"}],"container-title":["Recent Patents on Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1872208316666220106110014","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200056\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1872208316666220106110014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T04:02:27Z","timestamp":1691726547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200056\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872208316666220106110014","relation":{},"ISSN":["1872-2083"],"issn-type":[{"value":"1872-2083","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}